Abstract β 3 -Adrenoceptors are resistant to agonist-induced desensitization in some cell types but susceptible in others including transfected human embryonic kidney (HEK) cells. Therefore, we have studied cellular and molecular changes involved in agonist-induced β 3 -adrenoceptor desensitization in HEK cells. Cells were treated with isoprenaline or forskolin, and following wash-out, cyclic adenosine monophosphate (cAMP) accumulation in response to freshly added agonist was quantified. Receptor and G protein expression were quantified by radioligand binding and immunoblot experiments, respectively. Treatment with isoprenaline induced a concentration-and time-dependent desensitization of cAMP accumulation in response to freshly added isoprenaline. This functional desensitization primarily consisted of reduced maximum responses with little change of agonist potency. Maximum desensitization was achieved by pretreatment with 10 μM isoprenaline for 24 h. It was not accompanied by changes in β 3 -adrenoceptor density as assessed in saturation radioligand-binding studies. The desensitization was associated with a small reduction in immunoreactivity for α-subunits for G s and G i1 , whereas that for G i2 , G i3 , and G q/11 was not significantly altered. In cells treated with pertussis toxin, isoprenaline-induced cAMP accumulation as well as desensitization by isoprenaline pre-treatment remained unchanged. Isoprenaline pre-treatment also reduced forskolin-induced cAMP accumulation; conversely, pretreatment with forskolin caused a similar desensitization of isoprenaline-induced cAMP accumulation. We conclude that agonist-induced β 3 -adrenoceptor desensitization in HEK cells does not involve reduced receptor numbers and small, if any, reduction of G s expression; changes at the level of adenylyl cyclase function can fully explain this desensitization.
Introduction
Agonist-induced desensitization of cellular responses to stimulation of G protein-coupled receptors is a wide-spread biological phenomenon; e.g., for β-adrenoceptors, it can occur upon enhanced stimulation by endogenous neurotransmitters or hormones such as in chronic heart failure (Brodde et al. 2006 ) and after chronic agonist exposure such as with tocolytic therapy (Caritis et al. 1987; Frambach et al. 2005) . The cellular and molecular mechanisms underlying agonistinduced desensitization have largely been explored using the β 2 -adrenoceptor as a model (Barak et al. 1994; January et al. 1997; Scola et al. 2004; Tran et al. 2007) . In this context, short-term desensitization (within seconds to minutes) can involve phosphorylation of the receptor, uncoupling from its G proteins, and/or receptor internalization (January et al. 1997; Pippig et al. 1995) . However, the relevance of shortterm desensitization for chronic exposure to endogenous or exogenous receptor agonists remains unclear. Long-term desensitization (within hours to days) may have more relevance for the understanding of tachyphylaxis occurring during chronic treatment with agonists and may at least partly involve different molecular mechanisms than short-term desensitization (Hendriks-Balk et al. 2008) . Studies using β 1 -and/or β 2 -adrenoceptors as examples have demonstrated receptor down-regulation, at least partly occurring at the level of reduced mRNA abundance (Engelhardt et al. 1997; Hadcock and Malbon 1988) , and down-and up-regulation of G s and G i proteins, respectively (Adie and Milligan 1994; Chambers et al. 1994; Eschenhagen et al. 1992; Kimura et al. 1993; Marzo et al. 1991) , as targets of functional desensitization. A contribution of up-regulation of G i proteins to β-adrenoceptor desensitization can functionally be tested by inactivating G i using pertussis toxin (PTX) (Brown et al. 1990; Brown and Harding 1992) . β-Adrenoceptor desensitization can also involve a reduced function of the cyclic adenosine monophosphate (cAMP)-forming enzyme adenylyl cyclase (Feldman 1989; Medina-Martinez and Garcia-Sainz 1993) , and/or an increased activity of phosphodiesterases (Ortiz et al. 2000) , but the latter two only contribute to the cAMP part of β-adrenoceptor functions which may not be the only signaling pathway activated by β-adrenoceptors (Evans et al. 2010) . Interestingly, the susceptibility to agonist-induced down-regulation appears to differ between β-adrenoceptor subtypes with β 1 -adrenoceptors typically being less affected than β 2 -adrenoceptors, e.g., in the heart (Nanoff et al. 1989; Nanoff et al. 1990) .
β 3 -Adrenoceptors have been discovered more recently and mediate functions such as relaxation of urinary bladder smooth muscle (Michel et al. 2010 ) whereas their role in other tissues such as the human heart is controversial . Accordingly, selective β 3 -adrenoceptor agonists have recently been shown to be effective in the treatment of the overactive bladder syndrome (Khullar et al. 2013; Nitti et al. 2013; Ohlstein et al. 2012) . As the use of β 3 -adrenoceptor agonists in this indication is considered symptomatic rather than curative, long-term agonist treatment is expected to be required. This raises the question whether and how human β 3 -adrenoceptors are subject to agonist-induced desensitization.
For a long time, it had been believed that β 3 -adrenoceptors may be rather insensitive to agonist-induced desensitization as they lack the phosphorylation sites considered to be involved in short-term desensitization (Liggett et al. 1993; Nantel et al. 1993) . Accordingly, it has been shown that β 3 -adrenoceptors transfected into Chinese hamster ovary (CHO) cells (Candelore et al. 1996; Chambers et al. 1994; Chaudhry and Granneman 1994) , L and CHW cells (Nantel et al. 1993; or endogenously expressed β 3 -adrenoceptors in human SK-N-MC neuroblastoma cells (Curran and Fishman 1996) were resistant to both short-and long-term agonist-induced desensitization. On the other hand, studies in some other model systems have reported agonist-induced desensitization of β 3 -adrenoceptors. Desensitization studies in adipocytes have yielded a controversial picture, even if only species are considered where this is mediated by a β 3 -adrenoceptor. Lipolytic responses in hamster did not exhibit desensitization in response to prolonged in vivo noradrenaline treatment (Carpene et al. 1993) . In contrast, surgical sympathectomy was reported to increase β 3 -adrenoceptor mRNA expression in rat brown adipose tissue, whereas cold exposure, known to increase sympathetic activity, decreased it (Granneman and Lahners 1992) . The cold exposure-induced mRNA down-regulation in rats was confirmed in another study with young but not senescent rats; in those animals, cold exposure in young but not old rats also caused desensitization of adipocyte cAMP formation in response to the β-adrenoceptor agonist BRL 37,344 (Scarpace et al. 1999) . Acute cold exposure in mice induced a marked albeit transient down-regulation of adipocyte β 3 -adrenoceptor mRNA (Bengtsson et al. 1996) . This down-regulation was mimicked by exposure to noradrenaline or forskolin; however, the proposed role of cAMP in causing mRNA down-regulation was not directly proven and no evidence for functional desensitization was provided. Down-regulation of murine adipocyte β 3 -adrenoceptor mRNA was also reported in response to the β 3 -adrenoceptor agonist CL 316,243 (Hutchinson et al. 2000) . The same study reported that the relaxation responses in mouse ileum were attenuated following a 4 or 24-h treatment with CL 316,243, but such desensitization was observed in the absence of changes of β 3 -adrenoceptor mRNA or binding sites. Moreover, this study found that the antagonist/biased agonist SR 59,230A increased β 3 -adrenoceptor mRNA in ileum and brown but not white adipose tissue; the increase in ileum was accompanied by an elevated number of binding sites and enhanced relaxation responses. Treatment with forskolin reduced β 3 -adrenoceptor mRNA in brown and white adipose tissue, whereas mRNA and relaxation responses to CL 316,243 in ileum remained unaffected. Limited but consistent data with human β 3 -adrenoceptors transfected into HEK cells, in contrast to the above findings with CHO, L, or CHW cells, have also reported agonist-induced desensitization (Chaudhry and Granneman 1994; ), but it remains illdefined at which level of the signaling cascade this desensitization occurs. Therefore, the aim of the present study has been to explore agonist-induced long-term desensitization of human β 3 -adrenoceptors expressed in HEK cells, particularly to determine at which level desensitization occurs. L 748,337 (S)-N-[4-[2-[[3-[3-(acetamidomethyl) RO 20-1724 (4-[(3-butoxy-4-methoxyphenyl) -methyl]-2-imidazolidinone), PTX (dissolved at 10 μg ml −1 in sterile, isotonic NaCl/NaH 2 PO 4 buffer, pH 7.4) and forskolin (dissolved at 100 μM in dimethylsulfoxide) were purchased from Sigma Aldrich (Zwijndrecht, The Netherlands). All primary and secondary antibodies were from Santa Cruz (see below). CHO cells stably transfected with the human β 3 -adrenoceptor were a kind gift of Dr. Carsten Hoffmann (Niclauß et al. 2006) . HEK cells transfected with the human β 3 -adrenoceptor had been generated in our lab ). While the presence of β 1 -and β 2 -adrenoceptor mRNA has been detected in some HEK cells (Sumi et al. 2010 ), ours did not yield quantifiable isoprenaline-induced cAMP accumulation unless transfected with a cloned β-adrenoceptor (data not shown). Both cell lines were cultured as reported. For the desensitization experiments, the cells were cultured for 24 h in a serum-free medium in the presence of vehicle or 10-μM isoprenaline, unless otherwise indicated. Thereafter, cells were thoroughly washed and pre-incubated for 1 h in serum-free medium.
Methods

Materials
Cyclic AMP studies cAMP accumulation was determined as previously described ). Briefly, cells were detached from the surface using enzyme-free cell dissociation buffer and washed once with Hank's balanced salt solution (HBSS). They were resuspended in HBSS supplemented with 5 mM HEPES and 0.05 % bovine serum albumin. The stimulation mixture contained in a twofold concentration the β 3 -adrenoceptor agonists, the cAMP phosphodiesterase inhibitors IBMX and RO 20-1724 (100 μM each). Cells were added to the stimulation mixture 1:1 in a 384 well optiplate (625 cells well −1 in a total volume of 10 μl) and stimulated for 30 min at room temperature. Detection was previously described (Jongsma et al. 2006 ) using the LANCE® cAMP 384 Kit (PerkinElmer, Zaventem, Belgium) and measured after 3 h on a Victor plate reader (Wallac, PerkinElmer, Zaventem, Belgium).
Radioligand-binding studies
,337 saturation radioligand binding was performed as previously described (van Wieringen et al. 2011) . Briefly, cells at approximately 80 % confluence were washed with phosphate-buffered saline, harvested by scraping the culture flasks with a cell scraper, washed twice by centrifugation at 200 g, and then homogenized in ice-cold buffer (50 mM Tris, 0.5 mM EDTA, pH 7.5) with an Ultra-Turrax (Janke & Kunkel, Staufen, Germany) for 10 s at full speed and then twice for 20 s each at 2/3 speed. The homogenates were centrifuged for 20 min at 50,000 g at 4°C. The pellets were resuspended in buffer and stored at −80°C. Aliquots of the respective membrane preparation (approximately 50-100 μg protein/assay) were incubated in a total volume of 250 μl of binding buffer (10 mM Tris, 0.9 mN NaCl at pH 7.4) at 25°C for 60 min. Non-specific binding was defined using 100 μM isoprenaline. In saturation experiments, eight radioligand concentrations were used. All experiments were performed in duplicates in 96 well plates, and incubations were terminated by rapid vacuum filtration over Whatman GF/C using a FilterMate harvester (PerkinElmer, Zaventem, Belgium). The filter mats had been pre-treated for 2 h at 4°C with 0.1 % polyethylenimine. Each filter was washed with approximately 2-3 ml of ice-cold buffer. Radioactivity adherent to the filters was quantified in a TopCount NXT (PerkinElmer) using Microsint O (PerkinElmer) scintillator.
Immunoblots HEK cells were treated for 24 h with 10 μM isoprenaline or vehicle in serum-free medium. Thereafter, the cells were washed with phosphate-buffered saline, harvested, homogenized, and centrifuged as described above for the radioligand-binding studies. The pellets were resuspended in TED buffer (1 mM Tris, 0.5 mM EDTA, 1 mM dithiothreitol) and rehomogenized with the Ultra-Turrax for 10 s at full speed, and. 5× Sample buffer was added to aliquots of the homogenates in a 1:5 ratio, and the samples were boiled for 5 min. Aliquots, thereof, were loaded on SDS gels (NuPAGE NP0322, Invitrogen, Grand Island, NY) and electrophoresed for approximately 1 h at 40 mA, and proteins were blotted onto nitrocellulose membranes at 200 V with a starting current of 170 mA in a cold room. The following primary antibodies (all rabbit polyclonal) were used for detection of G protein α-subunits: G s (K20, SC-823, 1:400), G i1 (I-20, SC-391, 1:200), G i2 (T-19, SC-7276, 1:400), G i3 (C-10, SC-262, 1:400), G q/11 (C19, SC-392, 1:400). They were diluted in buffer supplemented with 1 % dry milk power (except 5 % for G s antibody). The blots were blocked for 2 h with TTBS supplemented with 5 % dry milk powder at 25°, washed twice for 10 min each with TTBS, incubated with the primary antibodies overnight a 4°C, washed twice for 10 min each with TTBS and then incubated for 1 h at 25°C with the secondary antibody (donkey anti-rabbit coupled to horseradish peroxidase, Amersham, NA9340, 1:2,000). Following two additional washing steps, luminescence signals were detected using the Lumi-Light PLUS kit (Roche Applied Science) by an LAS3000 (Fujifilm, Düsseldorf, Germany) and quantified using AIDA software (version 3.52, Raytest, Straubenhardt, Germany).
Data analysis
Protein content was measured according to Bradford (Bradford 1976 ) using bovine IgG as the standard. All data shown are mean values ± s.e. mean. In the cAMP experiments sigmoidal curves were fitted to the experimental data from each experiment to calculate pEC 50 and E max . Saturation radioligand binding experiments were analyzed by fitting rectangular hyperbolic functions to the experimental data. The statistical significance of group differences was assessed by paired two-tailed t tests, and a p <0.05 was considered significant. All curve fitting and statistical calculations were performed using the Prism program (Graphpad Software, San Diego, CA, USA).
After completion of the analysis of the CHO and HEK cell cAMP accumulation data, the corresponding raw data became irretrievable. Therefore, the HEK cell experiments were repeated with n=3-4. As the results from the first and second series of experiments were very similar with regard to potency, efficacy and desensitization of isoprenaline-induced cAMP accumulation, the present manuscript reports pooled data from both series of experiments.
Results
In confirmation of previously published data of other investigators (Candelore et al. 1996; Chaudhry and Granneman 1994) , no significant desensitization was observed in CHO cells transfected with human β 3 -adrenoceptors (pEC 50 7.76±0.17 vs. 7.65±0.08, E max 902±74 vs. 778±8 fmol well , n=11 for all experiments reported in this manuscript, p <0.0001; Fig. 1 ).
When HEK cells were pre-treated with various isoprenaline concentrations for 24 h, desensitization of the response to freshly added isoprenaline was concentration-dependent with half-maximal reduction occurring upon pre-treatment with about 10 nM isoprenaline (Fig. 2) . In time course experiments, the desensitization of the isoprenaline-induced cAMP accumulation by pre-treatment with 10 μM isoprenaline was already evident and approximately half-maximal after 2 h and after 6 or 12 h reached a degree comparable with that seen after 24 h (Fig. 3) . Therefore, all subsequent experiments were performed in HEK cells using treatment with 10 μM isoprenaline for 24 h.
Further experiments were designed to identify at which level this concentration-and time-dependent desensitization occurs. Pre-treatment with isoprenaline did not significantly change the number or affinity of β 3 -adrenoceptors as assessed in saturation radioligand-binding experiments (Fig. 4) .
To explore a role of altered G protein expression in the desensitization of cAMP accumulation, desensitization experiments were performed in the absence and presence of PTX. Treatment with PTX (100 ng ml −1 for 24 h) did not affect isoprenaline-induced cAMP accumulation or its desensitization by isoprenaline pre-treatment (Fig. 5) . In immunoblot experiments isoprenaline pre-treatment caused a 21 and 47 % reduction in the abundance of α-subunits of G s and G i1 , respectively, but not those of G i2 , G i3 , or G q/11 (Fig. 5) .
To further explore whether isoprenaline pre-treatment also affects post-receptor signaling, we determined its effect on forskolin-induced cAMP accumulation (Fig. 6) . Although formal pEC 50 and E max values could not be calculated due to low potency, forskolin-induced cAMP accumulation was similarly reduced by isoprenaline pre-treatment as that by isoprenaline. When using the opposite design, pre-treatment with forskolin (10 μM for 24 h) caused desensitization of isoprenaline-induced cAMP accumulation to a similar degree as seen with isoprenaline pre-treatment (Fig. 6) , i.e., pEC 50 was numerically but not significantly reduced from 8.02±0.09 to 7.39±0.27 whereas E max was markedly lowered from 818±73 to 234±15 fmol well −1 (n=6, p=0.006).
Discussion β 3 -Adrenoceptor agonists were shown to be effective in the symptomatic treatment of the overactive bladder syndrome (Khullar et al. 2013; Nitti et al. 2013; Ohlstein et al. 2012 ).
As such treatment requires long-term drug administration, the risk exists that agonist-induced desensitization may limit treatment efficacy as has been shown e.g., with β 2 -adrenoceptor agonists in the treatment of pre-term labor (Caritis et al. 1987; Frambach et al. 2005) . Previous studies in some cell types have indicated that β 3 -adrenoceptors, e.g., in CHO cells, may be relatively resistant to agonist-induced down-regulation, particularly as compared to β 1 -and β 2 -adrenoceptors (see Introduction). On the other hand, β 3 -adrenoceptors e.g., natively expressed in rat or mouse adipose tissue or transfected into HEK cells exhibited pronounced agonist-induced down-regulation of receptor mRNA and/or desensitization (see Introduction). Data in mouse ileum indicate that such desensitization may occur in the absence of corresponding changes of receptor expression at the mRNA or protein level (Hutchinson et al. 2000) . Therefore, we have used HEK cells to explore the level at which agonistinduced desensitization of β 3 -adrenoceptors occurs. In this regard, we have focused on long-term rather than short-term desensitization as the two types may differ with regard to underlying mechanisms (Hendriks-Balk et al. 2008 ) and because longterm desensitization may be more relevant to therapeutic chronic use of β 3 -adrenoceptor agonists.
In confirmation of previous findings, agonist-induced desensitization of β 3 -adrenoceptor-mediated cAMP accumulation was absent in CHO cells but present in HEK cells. In the latter cell type, it was concentration-and timedependent, thus, desensitization was evident as early as after 2 h of 10 μM isoprenaline pre-treatment, and for a 24 h pretreatment was detectable with as little as 10 nM isoprenaline, i.e., a concentration similar to the EC 50 of isoprenaline to stimulation cAMP formation. Pre-treatment for 6 h and more with 10 μM isoprenaline or with 100 nM or more isoprenaline for 24 h caused maximum desensitization. Further experiments were designed to explore at which level of the signaling cascade such desensitization occurs.
Receptor down-regulation is a typical component of longterm desensitization of β 1 -and β 2 -adrenoceptors. Our experiments indicate that marked β 3 -adrenoceptor desensitization in HEK cells can occur in the absence of receptor downregulation at the protein level, confirming data in mouse ileum (Hutchinson et al. 2000) . Incidentally, the lack of change of apparent K d values for the radioligand in these experiments confirms the effectiveness of our wash-out protocols for the isoprenaline being used during the pre-treatment period. The agonist-induced desensitization of β 2 -adrenoceptors may at least partly be modulated by receptor gene polymorphisms in vitro (Chong et al. 2000; Green et al. 1994 ) and in vivo (Bruck et al. 2003a; Bruck et al. 2003b ). In contrast, we have previously shown that the only frequent polymorphism within the human β 3 -adrenoceptor gene does not affect agonistinduced desensitization in HEK cells ) as it had also failed to affect the resistance to desensitization upon expression in CHO cells (Candelore et al. 1996) .
The down-regulation of β 1 -and β 2 -adrenoceptors can involve a reduction of steady state concentrations of corresponding mRNA (Bouvier et al. 1989; Hough and Chuang 1990) . For some but not all model systems and for some but not all desensitization paradigms, this has also been confirmed for β 3 -adrenoceptors (see Introduction). We have not explored expression changes at the mRNA level in the present study because the receptor in our transfected HEK cells is not under the control of the native but rather of a p r e -tr e a tm e n t w ith is o p r e n a lin e cytomegalovirus promoter and because receptor expression at the protein level did not change in our cells.
Agonist-induced desensitization of β 1 -and β 2 -adrenoceptors may also involve alterations of their signaling machinery including a down-regulation of G s and an up-regulation of G i proteins (Adie and Milligan 1994; Chambers et al. 1994; Eschenhagen et al. 1992; Kimura et al. 1993; Marzo et al. 1991) . Downregulation of G s upon extended β 3 -adrenoceptor stimulation has been reported in CHO cells in the absence of receptor downregulation but was not associated with functional desensitization (Chambers et al. 1994) . In the present study, a contribution of altered G protein expression was explored in two ways. Firstly, a functional role for up-regulated G i proteins was explored by comparing desensitization in control and in PTX-treated cells, an intervention which has been used to demonstrate the involvement to G i up-regulation in the desensitization of other β-adrenoceptor subtypes (Brown et al. 1990; Brown and Harding 1992) . However, in HEK cells, isoprenaline pretreatment-induced β 3 -adrenoceptor desensitization was similarly observed in cells with or without PTX treatment. Secondly, the expression of G s and G i proteins was assessed by immunoblotting. While the observed small reduction in G s immunoreactivity could potentially contribute to the observed functional desensitization, the observed reduction in G i1 and the lack of change in G i2 and G i3 immunoreactivity do not support a role for increased G i expression in desensitization, which is in line with our PTX experiments.
A reduced expression and/or function of adenylyl cyclase can also contribute to the desensitization of β 1 -and β 2 -adrenoceptors (Feldman 1989; Medina-Martinez and GarciaSainz 1993) . This mechanism apparently is also involved in the desensitization of β 3 -adrenoceptor-mediated cAMP accumulation in HEK cells as isoprenaline pre-treatment desensitized forskolin-stimulated cAMP formation to a similar extent as isoprenaline-induced formation. Given the difficulties of identifying a specific isoform of adenylyl cyclase as being reduced in activity (Erdorf and Seifert 2011; Kinast et al. 2012 ) and because it is uncertain whether the isoform of adenylyl cyclase affected in HEK cells is representative for that in target tissues such as the urinary bladder, no attempts were made to identify the isoform being functionally changed in our desensitization protocols. However, we have observed that forskolin pretreatment induced a similar degree of desensitization of the isoprenaline response as isoprenaline pre-treatment, indicating that this desensitization may involve cAMP-dependent protein kinase. An involvement of cAMP in β 3 -adrenoceptor mRNA down-regulation has been proposed in murine adipose tissue because forskolin mimicked the noradrenaline-induced downregulation (Bengtsson et al. 1996) . On the other hand, 8-BrcAMP did not mimic isoprenaline-induced desensitization in HEK cells (Chaudhry and Granneman 1994) , which does not support a role for cAMP in mediating the agonist-induced desensitization. The reason between conflicting results for a role of cAMP in causing desensitization may relate to different substrains of HEK cells, as those being used by Chaudhry and Granneman (1994) exhibited functional β 2 -adrenoceptors whereas ours did not. More definitive studies based on inhibitors of cAMP formation or protein kinase A remain to be done. A possible role of G protein-coupled receptor kinases was not investigated as these mostly play a role in short-term desensitization (Hendriks-Balk et al. 2008) . Moreover, the present study was designed to investigate at which level the desensitization occurs; the mechanisms causing such desensitization remain to be explored in future studies.
In conclusion, our data demonstrate a concentration-and time-dependent agonist-induced desensitization of β 3 -adrenoceptor-mediated cAMP accumulation in HEK cells. This does not involve receptor down-regulation, but rather, can be explained by a reduced activity of adenylyl cyclase and, perhaps, a reduced expression of G s proteins. These findings may be representative for those in some tissues such as rat and mouse brown adipose tissue or mouse ileum. However, they differ from those in CHO, L, CHW, and SK-N-MC cells or in hamster adipose tissue. Therefore, the susceptibility of β 3 -adrenoceptors to undergo agonist-induced desensitization appears to be cell type-dependent. Such differences between cell types necessitate studying agonist-induced desensitization specifically in the target tissues of β 3 -adrenoceptor agonists such as the urinary bladder to rule out that desensitization may limit therapeutic efficacy. Preliminary data from our lab indicate that β 3 -adrenoceptor function in rat bladder exhibits some degree of agonist-induced desensitization in response to one agonist (CL 316,243) but not to another one (mirabegron) , indicating that such desensitization may involve biased agonism. In a more general vein, our data highlight the idea that studies in transfected cells may or may not be a representative for those in target tissues and reinforce the importance of careful validation of results obtained in transfected cells.
